For patients requiring this medication, ensuring the purchase of genuine tepotinib is critically important. Currently, multiple formal channels are available, including hospital pharmacies, designated medical insurance pharmacies, and cross‑border medical platforms.
Legitimate Purchase Channels for Genuine Tepotinib
Hospital Pharmacy Purchase
The oncology pharmacy of domestic hospitals is one of the most reliable channels for purchasing tepotinib.Patients must present a doctor’s prescription and genetic testing report. Pharmacy staff will verify the information before dispensing the medication.Drugs from hospital pharmacies are directly sourced from authorized distributors, guaranteeing product quality.
Cross‑Border Medical Platform Purchase
For patients needing overseas versions, formal cross‑border medical platforms can be used.A complete prescription and diagnostic certificate are required for purchase. The platform will assist with customs declaration and related procedures.
Dosage and Administration of Tepotinib
Standard Dosage
The recommended dosage is 450 mg (2 tablets of 225 mg) orally once daily, taken with food.Tablets should be swallowed whole and must not be chewed, crushed, or split.Dosing at a fixed time each day is recommended to maintain stable plasma concentrations.
Missed Dose
If a dose is missed, take it as soon as remembered.If it is less than 8 hours until the next scheduled dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one.
Vomiting Management
If vomiting occurs after dosing, no replacement dose is needed. Take the next scheduled dose at the usual time.Patients with frequent vomiting should seek medical attention promptly; the physician may adjust the treatment regimen.
Regular follow‑up evaluations are required during treatment to assess efficacy and monitor adverse reactions.In the event of severe side effects, immediate medical attention is necessary, and the physician may adjust the dose or temporarily suspend treatment.
Use in Special Populations
Pregnant and Breastfeeding Women
Tepotinib causes embryo‑fetal toxicity and is contraindicated in pregnancy.Women of childbearing potential should undergo a pregnancy test before treatment and use effective contraception during treatment and for 1 week after the last dose.Breastfeeding women should discontinue breastfeeding to avoid infant exposure via breast milk.
Geriatric Patients
No dose adjustment is required for patients aged 65 years and older.However, due to frequent comorbidities in the elderly, enhanced monitoring is recommended during treatment, especially of hepatic, renal, and cardiovascular function.
Patients with Hepatic or Renal Impairment
No dose adjustment is needed in patients with mild or moderate hepatic impairment.
Contraindicated in patients with severe hepatic impairment.
Dose adjustment based on creatinine clearance is recommended for patients with renal impairment.
Tepotinib should be used with caution in patients with severe renal impairment.
